GleamWall
中文EN

RXST RxSight, Inc.

Ophthalmic Goods · Nasdaq · SEC CIK 1111485 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-14.3%
TTM net income YoY-49.3%
TTM EPS YoY-46.6%
Revenue 3-yr CAGR16.7%
Net income 3-yr CAGR—

Margins

Gross margin76.1%
Operating margin-50.4%
Net margin-43.8%
FCF margin15.3%
EBITDA margin-47.5%

Returns

ROE-20.1%
ROA-16.4%
ROIC (approx.)-22.4%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets25.1%
Debt / equity0.00x
Current ratio4.20x
Interest coverage-4,389.57x

Cash quality & payout

Operating cash flow / net income-0.44x
Accruals ratio-23.7%
Payout ratio—
Capex / revenue4.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$24.59M$33.74M$30.89M$32.61M$30.34M$33.64M$37.90M$40.21M
Cost of revenue$6.49M$7.86M$7.39M$7.34M$6.11M$8.45M$9.57M$11.43M
Gross profit$18.10M$25.89M$23.50M$25.26M$24.23M$25.19M$28.33M$28.79M
R&D expense$9.21M$9.24M$9.47M$8.90M$9.06M$10.22M$10.37M$9.21M
SG&A expense$27.40M$30.42M$31.86M$27.70M$27.34M$28.98M$28.64M$28.21M
Operating income-$18.52M-$13.77M-$17.83M-$11.34M-$12.18M-$14.00M-$10.67M-$8.63M
Interest expense$3,000$3,000$3,000$5,000$4,000$5,000$6,000$5,000
Pretax income-$16.20M-$12.01M-$15.88M-$9.15M-$9.81M-$11.75M-$8.17M-$5.93M
Income tax$28,000$88,000$6,000$5,000$10,000$32,000$18,000$12,000
Net income-$16.22M-$12.10M-$15.88M-$9.15M-$9.82M-$11.79M-$8.19M-$5.94M
EBITDA-$17.59M-$12.77M-$17.00M-$10.49M-$11.32M-$13.22M-$9.90M-$8.11M
EPS (basic)-0.39-0.29-0.38—-0.24-0.29-0.20—
EPS (diluted)-0.39-0.29-0.38—-0.24-0.29-0.20—
Weighted avg. shares (diluted)41.71M41.49M41.31M—40.97M40.74M40.51M—
Balance sheet
Cash & equivalents$66.72M$13.35M$17.57M$19.95M$30.38M$41.10M$28.75M$17.46M
Short-term investments$187.97M$195.45M$200.31M$208.18M$197.88M$187.14M$201.34M$220.52M
Receivables$17.00M$18.52M$22.44M$23.38M$24.15M$28.06M$30.96M$30.05M
Inventory$39.59M$37.12M$34.87M$31.56M$28.95M$25.06M$23.57M$22.01M
Current assets$314.80M$327.40M$279.23M$287.46M$283.88M$283.87M$288.41M$293.82M
PP&E, net$14.65M$14.04M$13.23M$13.06M$13.10M$13.26M$12.56M$12.41M
Total assets$340.42M$352.70M$303.99M$311.81M$308.53M$309.01M$313.04M$318.56M
Current liabilities$74.95M$80.44M$27.38M$26.25M$22.29M$20.38M$22.74M$25.88M
Total liabilities$85.51M$89.36M$36.70M$36.13M$32.56M$31.00M$33.73M$37.33M
Shareholders' equity$254.91M$263.34M$267.30M$275.68M$275.97M$278.01M$279.32M$281.24M
Shares outstanding41.93M41.59M41.38M41.24M41.08M40.91M40.59M40.43M
Cash flow statement
Operating cash flow$45.22M-$9.54M-$10.89M-$1.12M-$1.19M-$4.38M-$8.83M-$4.26M
Capital expenditure$1.17M$1.96M$759,000$1.14M$581,000$1.54M$575,000$847,000
Free cash flow$44.04M-$11.49M-$11.65M-$2.25M-$1.77M-$5.91M-$9.41M-$5.11M
Investing cash flow$7.95M$4.65M$8.85M-$9.61M-$9.00M$14.65M$20.86M$1.32M
Financing cash flow$195,000$662,000-$336,000$1.06M-$530,000$2.06M-$735,000$2.98M
Depreciation & amortization$929,000$999,000$834,000$851,000$854,000$785,000$776,000$515,000
Stock-based compensation$7.63M$7.46M$7.95M$7.82M$8.11M$8.55M$7.14M$7.28M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.